In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available
Scientific Claim
In virally suppressed, abdominally obese individuals with HIV, tesamorelin-induced changes in insulin-like growth factor 1 levels are not associated with changes in neurocognitive performance or waist circumference.
Original Statement
“IGF-1 levels increased, but changes did not correlate with summary regression change score or WC.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design allows for association claims, and the abstract explicitly states no correlation between IGF-1 changes and the outcomes, so the claim is appropriately phrased.
Evidence from Studies
Supporting (1)
Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.